CJC-1295 + Ipamorelin Blend: Product Details, Quality and Ordering
CJC 1295 ipamorelin research brings two growth-hormone-axis pathways into the same laboratory preparation. One component is intended to model signalling through the growth hormone-releasing hormone receptor, while ipamorelin is a growth hormone secretagogue associated with the ghrelin receptor.
At Peptide King, our CJC-1295 without DAC 5mg + Ipamorelin 5mg blend is listed as a lyophilized research preparation for in-vitro laboratory use only. The live product page states 5mg of each component, ≥98% HPLC-verified purity, storage at -20°C protected from light, and separate molecular specifications for the two peptides.
This guide explains what each component represents, why the naming of CJC-1295 matters, what the research actually supports, and what laboratories should verify before using a two-component peptide blend.
What Is the CJC 1295 Ipamorelin Blend?
The blend combines a 29-amino-acid GHRH-pathway peptide with ipamorelin, a five-amino-acid growth hormone secretagogue. The two components are associated with different receptor systems that both connect to growth hormone signalling.
The CJC Component Targets the GHRH Pathway
Peptide King describes its first component as CJC-1295 without DAC, or GRF 1-29, with a molecular weight of 3367.97 g/mol.
Growth hormone-releasing hormone normally signals through the GHRH receptor on pituitary somatotroph cells. Modified GRF 1-29 analogues are studied because changes to the native sequence can alter stability while retaining GHRH-receptor activity.
The naming needs care, however. The original peer-reviewed molecule called CJC-1295 was designed with an albumin-binding modification that extended its circulation time. Peptide King’s “without DAC” material is therefore not the same molecular design as the long-acting CJC-1295 described in those original studies.
Ipamorelin Uses a Different Receptor Pathway
Ipamorelin is a pentapeptide growth hormone secretagogue. Early pharmacology identified it as a selective GHRP-receptor agonist capable of stimulating GH release in experimental models.
Because the two components approach GH-axis signalling through different receptors, the blend can support laboratory questions involving parallel receptor pathways. That does not establish clinical synergy or prove that the combination produces a stronger biological result than either peptide alone.
Why Does the “Without DAC” Name Matter?
This is one of the most important quality questions for CJC-related research products.
Original CJC-1295 Was an Albumin-Binding Analogue
The 2005 CJC-1295 research described a tetrasubstituted GRF 1-29 analogue carrying a reactive group designed to bind serum albumin. That modification was central to the compound’s extended pharmacokinetics.
Using those long-acting CJC-1295 results to describe a no-DAC GRF-style material would blur two different molecules.
Product Documentation Should Define the Material in Front of You
For a laboratory, the commercial name is only the first identifier.
The useful record should include sequence or peptide length, molecular weight, chemical form, lot number, purity method, and identity testing. With CJC-1295 without DAC, those details are especially important because the marketplace name is broader than the original peer-reviewed CJC-1295 structure.
What Does the Peptide King Product Page Specify?
The live CJC-1295 without DAC + Ipamorelin page provides a clear two-component specification.
Each Component Has Its Own Listed Quantity
The page lists:
- CJC-1295 without DAC: 5mg
- Ipamorelin: 5mg
- Form: lyophilized powder
- Purity: ≥98% HPLC verified
- Storage: -20°C protected from light
- CJC component: 3367.97 g/mol, 29 amino acids
- Ipamorelin: 711.85 g/mol, five amino acids
Those specifications are more useful than treating the vial as one undifferentiated “10mg blend.”
The Current Page Does Not Display a Visible CoA Link
The product page states HPLC-verified purity, but it does not currently show a visible Certificate of Analysis link.
For a two-peptide product, we would want batch documentation that supports the identity and composition of both components. A single overall purity percentage does not tell a researcher whether each peptide was independently identified or quantified.
What Does the Ipamorelin Evidence Actually Show?
Ipamorelin has both preclinical pharmacology and limited human research, but those findings should be interpreted separately.
Early Research Established Selective GH-Secretagogue Activity
A 1998 study characterized ipamorelin as a selective growth hormone secretagogue. In animal models, it stimulated GH release with less ACTH or cortisol response than some comparison secretagogues.
A Human Phase 2 Study Did Not Show Significant Efficacy
Ipamorelin was later tested in a randomized, double-blind Phase 2 trial involving 117 bowel-resection patients. The study evaluated postoperative ileus and found no statistically significant improvement in its key or secondary efficacy outcomes versus placebo.
That is a useful reminder that receptor activity and clinical efficacy are different questions.
How Should Researchers Evaluate a Two-Peptide Blend?
A blend creates more analytical questions than a single peptide because both components should be documented.
Use a Two-Component Verification Checklist
| Detail | What to verify |
|---|---|
| CJC component | Sequence, molecular weight and naming |
| Ipamorelin | Identity and molecular specification |
| Quantity | Measured content for each component |
| HPLC purity | Method and chromatographic results |
| Identity testing | Appropriate support for both peptides |
| Lot number | Connection to current inventory |
| Physical form | Matches the product specification |
| Test date | Relevant to the current batch |
Purity Does Not Prove Composition
A high HPLC purity result is useful, but it does not automatically establish that a nominal 5mg + 5mg blend contains the expected amount of each peptide.
For blend research, identity, purity, and quantity should be treated as separate data points.
How Does This Blend Compare With Tesamorelin?
Peptide King also lists Tesamorelin 10mg, another GHRH-pathway research compound.
Similar Pathways Do Not Make the Molecules Interchangeable
Tesamorelin is a 44-amino-acid GHRH analogue with a substantial pharmaceutical research history. The CJC component in this blend is listed as a 29-amino-acid GRF-style analogue, while ipamorelin targets the ghrelin receptor pathway.
Those structural and receptor differences matter when choosing a laboratory model.
What Is the Canadian Regulatory Context?
Health Canada specifically lists CJC-1295 and ipamorelin among injectable peptide drugs regulated as prescription drugs in Canada. It also states that “For Research Use Only” labelling does not automatically exempt a product from regulatory requirements.
Peptide King states that this blend is intended only for in-vitro laboratory research and is not for human or animal consumption.
Researchers should confirm that procurement and use comply with applicable laws, licences, ethics approvals, and institutional rules.
How We Present CJC-1295 + Ipamorelin at Peptide King
At Peptide King, we think the CJC 1295 ipamorelin blend should be understood as two defined research components, not as a shortcut to broad performance claims.
Start with the pathway. Then verify the molecule.
Review what “without DAC” means on the product page, confirm both component specifications, request current lot-specific analytical documentation, and keep mechanistic evidence separate from clinical outcomes.
A two-peptide vial only becomes useful research material when the identity and quality of both components are clear.